Pliant Therapeutics, Inc. (PLRX) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $1.19 (+3.95%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 12, 2026 | Yasmeen Rahimi | Piper Sandler | $3.00 | +153.2% |
| Sep 13, 2024 | Ed Arce | H.C. Wainwright | $38.00 | +3106.8% |
| Sep 9, 2024 | Faisal Khurshid | Leerink Partners | $33.00 | +2684.8% |
| May 23, 2024 | Yasmeen Rahimi | Piper Sandler | $40.00 | +3275.5% |
| May 7, 2024 | Alex Thompson | Stifel Nicolaus | $32.00 | +2600.4% |
| May 7, 2024 | Jeff Jones | Oppenheimer | $48.00 | +3950.6% |
| May 7, 2024 | Ed Arce | H.C. Wainwright | $36.00 | +2938.0% |
| May 7, 2024 | Brian Abrahams | RBC Capital | $45.00 | +3697.5% |
Top Analysts Covering PLRX
PLRX vs Sector & Market
| Metric | PLRX | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.50 | 2.24 | 2.40 |
| Analyst Count | 2 | 8 | 19 |
| Target Upside | +159.7% | +11474.8% | +17.1% |
| P/E Ratio | -0.50 | 3.91 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $3M | $3M | $3M | 6 |
| 2027-12-31 | $5M | $5M | $5M | 6 |
| 2028-12-31 | $25M | $25M | $25M | 5 |
| 2029-12-31 | $15M | $15M | $15M | 2 |
| 2030-12-31 | $108M | $108M | $108M | 2 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-1.78 | $-1.51 | $-1.24 | 4 |
| 2027-12-31 | $-1.53 | $-1.19 | $-0.99 | 4 |
| 2028-12-31 | $-2.05 | $-1.09 | $-0.27 | 4 |
| 2029-12-31 | $-1.25 | $-1.25 | $-1.25 | 2 |
| 2030-12-31 | $-0.93 | $-0.93 | $-0.93 | 2 |
Frequently Asked Questions
What is the analyst consensus for PLRX?
The consensus among 2 analysts covering Pliant Therapeutics, Inc. (PLRX) is Buy with an average price target of $3.00.
What is the highest price target for PLRX?
The highest price target for PLRX is $48.00, set by Jeff Jones at Oppenheimer on 2024-05-07.
What is the lowest price target for PLRX?
The lowest price target for PLRX is $3.00, set by Yasmeen Rahimi at Piper Sandler on 2026-03-12.
How many analysts cover PLRX?
2 analysts have issued ratings for Pliant Therapeutics, Inc. in the past 12 months.
Is PLRX a buy or sell right now?
Based on 2 analyst ratings, PLRX has a consensus rating of Buy (2.50/5) with a +159.7% upside to the consensus target of $3.00.
What are the earnings estimates for PLRX?
Analysts estimate PLRX will report EPS of $-1.51 for the period ending 2026-12-31, with revenue estimated at $3M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.